Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$268.74 +0.7%	$292.52	$262.21 ▼ $495.55	$35.65B	0.27	1.50 million shs	1.14 million shs
BIIB Biogen	$200.62 +1.5%	$199.60	$124.56 ▼ $219.72	$29.19B	0.16	1.46 million shs	1.03 million shs
INCY Incyte	$116.69 +0.8%	$106.38	$69.69 ▼ $119.60	$23.13B	0.76	1.66 million shs	956,158 shs
IONS Ionis Pharmaceuticals	$55.87 +3.4%	$71.96	$40.03 ▼ $86.74	$8.93B	0.36	4.39 million shs	3.83 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-1.61%	-4.35%	-6.78%	-14.91%	-17.92%
BIIB Biogen	-2.67%	+0.25%	-0.99%	+5.25%	+54.67%
INCY Incyte	-1.36%	+0.61%	+11.70%	+21.28%	+68.06%
IONS Ionis Pharmaceuticals	+1.16%	-1.32%	-28.83%	-27.10%	+28.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$268.74 +0.7%	$292.52	$262.21 ▼ $495.55	$35.65B	0.27	1.50 million shs	1.14 million shs
BIIB Biogen	$200.62 +1.5%	$199.60	$124.56 ▼ $219.72	$29.19B	0.16	1.46 million shs	1.03 million shs
INCY Incyte	$116.69 +0.8%	$106.38	$69.69 ▼ $119.60	$23.13B	0.76	1.66 million shs	956,158 shs
IONS Ionis Pharmaceuticals	$55.87 +3.4%	$71.96	$40.03 ▼ $86.74	$8.93B	0.36	4.39 million shs	3.83 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-1.61%	-4.35%	-6.78%	-14.91%	-17.92%
BIIB Biogen	-2.67%	+0.25%	-0.99%	+5.25%	+54.67%
INCY Incyte	-1.36%	+0.61%	+11.70%	+21.28%	+68.06%
IONS Ionis Pharmaceuticals	+1.16%	-1.32%	-28.83%	-27.10%	+28.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.85	Moderate Buy	$452.13	68.24% Upside
BIIB Biogen	2.53	Moderate Buy	$220.57	9.94% Upside
INCY Incyte	2.36	Hold	$111.10	-4.79% Downside
IONS Ionis Pharmaceuticals	2.77	Moderate Buy	$95.90	71.65% Upside

Current Analyst Ratings Breakdown

Latest IONS, ALNY, BIIB, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	INCY Incyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$103.00 ➝ $104.00
7/23/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/23/2026	INCY Incyte	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$105.00 ➝ $110.00
7/22/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$420.00 ➝ $400.00
7/21/2026	BIIB Biogen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$260.00 ➝ $280.00
7/21/2026	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$106.00 ➝ $89.00
7/21/2026	BIIB Biogen	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$217.00 ➝ $215.00
7/21/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$140.00
7/17/2026	IONS Ionis Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	IONS Ionis Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Peer Perform
7/15/2026	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform

(Data available from 7/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.29B	8.37	$2.77 per share	97.05	$5.97 per share	45.02
BIIB Biogen	$9.94B	2.98	$22.34 per share	8.98	$124.45 per share	1.61
INCY Incyte	$5.14B	4.53	$6.14 per share	18.99	$26.32 per share	4.43
IONS Ionis Pharmaceuticals	$1.06B	8.73	N/A	N/A	$3.02 per share	18.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$3.66	73.43	27.04	N/A	11.72%	85.76%	10.32%	7/30/2026 (Estimated)
BIIB Biogen	$1.29B	$9.32	21.53	12.35	N/A	13.81%	12.83%	8.01%	7/29/2026 (Estimated)
INCY Incyte	$1.29B	$7.08	16.48	14.94	1.06	26.71%	26.66%	19.77%	7/28/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$2.07	N/A	N/A	N/A	-30.91%	-58.65%	-10.07%	7/29/2026 (Estimated)

Latest IONS, ALNY, BIIB, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	N/A	N/A	N/A	$1.32 billion	N/A
7/29/2026	Q2 2026	BIIB Biogen	$3.13	N/A	N/A	N/A	$2.46 billion	N/A
7/29/2026	Q2 2026	IONS Ionis Pharmaceuticals	-$1.0914	N/A	N/A	N/A	$189.06 million	N/A
7/28/2026	Q2 2026	INCY Incyte	$2.10	N/A	N/A	N/A	$1.47 billion	N/A
4/30/2026	Q1 2026	ALNY Alnylam Pharmaceuticals	$0.8720	$1.99	+$1.1180	$1.51	$1.12 billion	$1.17 billion
4/29/2026	Q1 2026	BIIB Biogen	$2.95	$3.57	+$0.62	$2.15	$2.29 billion	$2.48 billion
4/29/2026	Q1 2026	IONS Ionis Pharmaceuticals	-$0.85	-$0.56	+$0.29	-$0.56	$195.57 million	$246.09 million
4/28/2026	Q1 2026	INCY Incyte	$1.38	$1.81	+$0.43	$1.47	$1.22 billion	$1.27 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.94	3.13	3.06
BIIB Biogen	0.34	3.06	2.41
INCY Incyte	0.01	3.68	3.60
IONS Ionis Pharmaceuticals	2.75	4.10	4.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
INCY Incyte	96.97%
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
INCY Incyte	16.20%
IONS Ionis Pharmaceuticals	1.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.51 million	132.37 million	Optionable
BIIB Biogen	7,500	147.64 million	147.27 million	Optionable
INCY Incyte	2,844	199.78 million	167.42 million	Optionable
IONS Ionis Pharmaceuticals	1,402	165.26 million	162.27 million	Optionable

IONS, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

July 23 at 11:30 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

July 23 at 10:00 AM | prnewswire.com

Hsbc Holdings PLC Acquires 159,026 Shares of Ionis Pharmaceuticals, Inc. $IONS

July 23 at 4:47 AM | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) Sees Unusually-High Trading Volume - Time to Buy?

July 22 at 11:59 AM | marketbeat.com

Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline

July 22 at 11:01 AM | zacks.com

Ionis Pharmaceuticals (IONS) Expected to Post Earnings on Wednesday

July 22 at 7:10 AM | marketbeat.com

114,334 Shares in Ionis Pharmaceuticals, Inc. $IONS Purchased by SEB Asset Management AB

July 22 at 5:04 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

July 21 at 1:27 PM | globenewswire.com

25,886 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Florida Financial Advisors LLC

July 21 at 4:07 AM | marketbeat.com

Ionis Pharmaceuticals' (IONS) "Peer Perform" Rating Reiterated at Wolfe Research

July 19, 2026 | americanbankingnews.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 17, 2026 | americanbankingnews.com

Ionis Pharmaceuticals: The Heartbreak Is Priced In

July 16, 2026 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

July 16, 2026 | prnewswire.com

Ionis Pharmaceuticals (NASDAQ:IONS) Given "Peer Perform" Rating at Wolfe Research

July 16, 2026 | marketbeat.com

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

July 15, 2026 | globenewswire.com

Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data

July 15, 2026 | zacks.com

Ionis to hold second quarter 2026 financial results webcast

July 15, 2026 | businesswire.com

Biogen drops after additional mid-stage trial data for Ionis-partnered Alzheimer’s drug

July 14, 2026 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

July 14, 2026 | globenewswire.com

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS

July 14, 2026 | globenewswire.com

Ionis Begins Dosing in Phase I/II Dravet Syndrome Study

July 14, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IONS, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$268.74 +1.75 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$265.36 -3.38 (-1.26%)

As of 07:55 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$200.62 +2.88 (+1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$200.46 -0.16 (-0.08%)

As of 07:56 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Incyte NASDAQ:INCY

$116.69 +0.90 (+0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$116.02 -0.67 (-0.57%)

As of 07:59 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Ionis Pharmaceuticals NASDAQ:IONS

$55.87 +1.86 (+3.44%)

Closing price 04:00 PM Eastern

Extended Trading

$55.74 -0.13 (-0.24%)

As of 07:55 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ALNY, BIIB, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ALNY, BIIB, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Incyte NASDAQ:INCY

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ALNY, BIIB, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ALNY, BIIB, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ALNY, BIIB, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ALNY, BIIB, and INCY Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Incyte NASDAQ:INCY

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools